Deucravacitinib
Chemical compound
Deucravacitinib, sold under the brand name Sotyktu, is a medication used for the treatment of moderate-to-severe plaque psoriasis. It is a tyrosine kinase 2 (TYK2) inhibitor and it is taken by mouth. It was developed by Bristol Myers Squibb.
Nº Q113940477 ★★
Incomum · Saberes
Deucravacitinib
Chemical compound
Deucravacitinib, sold under the brand name Sotyktu, is a medication used for the treatment of moderate-to-severe plaque psoriasis. It is a tyrosine kinase 2 (TYK2) inhibitor and it is taken by mouth. It was developed by Bristol Myers Squibb.
Último preço
—
Preço mínimo
—
Mediana 7 d
—
Vendas 30 d
0
Faixa 30 d
—
Em circulação
0
Cotação
mediana
mín – máx
vendas
Sem vendas no período
Ver tabela
| Data | mediana | Mín | Máx | vendas |
|---|
Histórico de vendas
- Última venda
- —
- Média 30 d
- —
- Mínima 30 d
- —
- Máxima 30 d
- —
- Vendas 7 d
- 0
- Vendas 30 d
- 0
Ainda sem vendas.
Vendas anônimas: sem comprador nem vendedor. Os números contam só vendas entre jogadores.
Na Wikipédia
Texto em inglês Ainda não há artigo no seu idioma: trecho em inglês.
Deucravacitinib, sold under the brand name Sotyktu, is a medication used for the treatment of moderate-to-severe plaque psoriasis. It is a tyrosine kinase 2 (TYK2) inhibitor and it is taken by mouth. It was developed by Bristol Myers Squibb. Deucravacitinib was approved for medical use in the United States in September 2022, and in Australia in December 2022. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Texto: Wikipédia em inglês, CC BY-SA 4.0. · Imagem: Vaccinationist (Public domain) ·
